FALLOPIAN TUBE CANCER

This study is testing whether a combination of two drugs, mirvetuximab soravtansine and olaparib, can help keep cancer from growing back in women whose ovarian, peritoneal, or fallopian tube cancer has returned but responded well to platinum-based chemotherapy. The goal is to see…

This study is testing whether a combination of two oral drugs, senaparib and temozolomide, can shrink tumors in women with a specific type of recurrent ovarian cancer that has a genetic change called ARID1A. It is for women whose cancer has come back after prior treatments. The m…

This study is testing whether adding a targeted drug called olaparib to a specialized surgery improves outcomes for advanced ovarian cancer. During surgery, doctors wash the abdomen with heated chemotherapy (HIPEC). Researchers want to see if taking olaparib pills for a week befo…

This study is for women whose ovarian cancer has returned but responded well to a second round of platinum chemotherapy. It tests if adding a newer, targeted drug (mirvetuximab soravtansine) to a standard maintenance drug (bevacizumab) can keep the cancer controlled longer and pr…

This is the first study in people for a new oral drug called AVZO-021. It aims to find a safe dose and see if the drug can help control advanced solid tumors, including certain types of breast and ovarian cancer, that have stopped responding to standard treatments. The study will…

This study is testing an experimental drug called ubamatamab for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. The goal is to see if the drug is safe and effective when given alone or…

This early-stage study is testing a new drug called XMT-1660 in people with advanced solid tumors that have returned or spread. The main goals are to find a safe dose and see what side effects occur. Researchers will enroll about 319 participants with cancers including triple-neg…

This early-stage study is testing a new cell therapy called FT536 for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The therapy involves collecting and modifying a patient's own immune cells, then giving them back directly into the abdomen. The main …

This study is testing whether new maintenance drugs can help women with recurrent ovarian cancer live longer without their cancer getting worse. After completing standard chemotherapy, participants will receive either the new drug combinations or standard care to see which works …

This early-stage study is testing if adding aspirin to standard chemotherapy helps the body's immune system better fight ovarian, fallopian tube, or peritoneal cancer. It will involve 100 adults who are scheduled for chemotherapy before surgery. Researchers will measure changes i…

This early-stage study is testing the safety and initial effectiveness of an experimental treatment called 27T51, a type of CAR T-cell therapy, for women with recurrent or hard-to-treat ovarian, primary peritoneal, or fallopian tube cancers. The first part will find the safest do…

This study is testing whether removing specific lymph nodes near the liver and stomach is safe and effective for women with advanced or returning ovarian cancer. Researchers will follow 94 patients who have this specialized surgery to see if it helps control the cancer longer. Th…

This study is testing an experimental drug called TORL-1-23 for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. The drug specifically targets cancer cells that have a protein called CLD…

This study is testing a new oral drug called ART0380 in people with advanced or metastatic solid tumors that have spread and are hard to treat. The main goals are to find the safest and most effective dose of ART0380 when given alone or combined with standard chemotherapy drugs, …

This study is testing a new drug called IMGN151, both by itself and combined with other cancer treatments, for women with certain gynecologic cancers like ovarian cancer. The main goals are to find safe doses and see if the treatments help control the cancer. About 377 participan…

This study is testing whether a new targeted drug called mirvetuximab soravtansine, when combined with standard chemotherapy (carboplatin), can shrink tumors before surgery in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The treatment is designed to…

This study is testing a new experimental drug, REGN5668, alone and in several combinations with other cancer drugs, for people with advanced ovarian, fallopian tube, peritoneal, or uterine cancers that have progressed after standard treatments. The main goals are to find the safe…

This study is for people with advanced ovarian cancer who have had successful surgery to remove all visible tumor. It aims to find out if receiving 3 cycles of standard chemotherapy, followed by a maintenance drug called niraparib, is as effective at preventing the cancer from co…

This study is testing if adding an experimental drug called IMNN-001 to standard chemotherapy and bevacizumab is safe and more effective at controlling advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will compare the two-drug standard treatment to the …

This large international study is testing which treatment strategy works better to control advanced ovarian, fallopian tube, or peritoneal cancer after initial chemotherapy. It compares taking the drug niraparib alone versus taking niraparib plus another drug called bevacizumab. …

This early-stage study is testing whether combining two drugs, Cirtuvivint and Olaparib, is safe and tolerable for women with a specific type of ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The trial will enroll about 50 women who have alrea…

This study is testing whether adding an experimental drug called relacorilant to standard chemotherapy helps control advanced gynecologic cancers. It will enroll about 270 patients with ovarian, fallopian tube, peritoneal, or endometrial cancer that has returned or spread. The ma…

This study is testing a new drug called Rina-S in people whose solid tumor cancers have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for people with several types of advanced cancer, including ovarian,…

This study is testing whether a blood conservation technique called acute normovolemic hemodilution (ANH) can reduce the need for donor blood transfusions during ovarian cancer surgery. Researchers will randomly assign 86 patients undergoing surgery for advanced ovarian cancer to…

This large Phase 3 trial is testing whether adding a new drug called IMNN-001 to standard chemotherapy helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer. About 500 participants will be randomly assigned to receive either the standard che…

This study is testing if a modified virus called Olvi-Vec, given directly into the abdomen, can help chemotherapy work better for women with ovarian cancer that has stopped responding to standard platinum drugs. Participants will be randomly assigned to receive either the virus f…

This study is testing a new approach to prevent ovarian cancer in women with specific genetic mutations that put them at high risk. Currently, the standard prevention is to remove both fallopian tubes and ovaries at a relatively young age, which causes immediate menopause. This s…

This study aims to better understand how ovarian, fallopian tube, and primary peritoneal cancers behave in patients with different genetic backgrounds. Researchers will observe 1000 women across four Nordic countries as they receive standard treatments, tracking their outcomes fo…

This study aims to understand how a drug called itraconazole, often used to treat fungal infections, affects the levels of a new experimental cancer drug (AZD5335) in the body. It will involve about 24 people with advanced ovarian, fallopian tube, or primary peritoneal cancer who…